We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
One More Step to Finalize Your Registration
An activation link has been sent to your email address.
Please check the email and activate your account now. It might take few minutes to get the email.
If you did not find it, please check your spam box.
Having problem receiving the email? Send again
Still cannot receive? Contact us
Email :PharmaSources@imsinoexpo.com
Whatsapp :+86-13621645194
Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa
Sample Provided: no
Payment Terms: CIF
"In the treatment of non-small cell lung cancer (NSCLC), combined with NP, MVP chemotherapy, this product can be tried in ineffective therapy for advanced or recurrent NSCLC patients with other methods. In the treatment of non-Hodgkin's lymphoma (NHL), combined therapy with BACOP chemotherapy, also can be used in trial by chemotherapy or other methods in the treatment of advanced NHL of invalid patients. Registration Dossiers:non-clinical & clinical part, drug substance part and drug product part." "Highlights: 1, Promoting the concentration of chemotherapeutic drugs in tumor by four to six times 2,Owning synergistic effect by combining various chemotherapeutics 3,Promoting chemotherapeutic effect of late NSCLC and NHL significantly 4, Efficacy of Monotherapy in Malignant pleural effusion and ascites: 87% 5, Time to market: 2004 6, Originator: Beromun,Tasonermin® by Boehringer Ingelbeim Registration Dossiers:non-clinical & clinical part, drug substance part and drug product part."